These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 18464023)

  • 1. Estetrol review: profile and potential clinical applications.
    Coelingh Bennink HJ; Holinka CF; Diczfalusy E
    Climacteric; 2008; 11 Suppl 1():47-58. PubMed ID: 18464023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications for estetrol.
    Visser M; Coelingh Bennink HJ
    J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):85-9. PubMed ID: 19167495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women.
    Coelingh Bennink HJ; Verhoeven C; Zimmerman Y; Visser M; Foidart JM; Gemzell-Danielsson K
    Maturitas; 2016 Sep; 91():93-100. PubMed ID: 27451327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic lupus erythematosus and hormone replacement therapy.
    Gompel A; Piette JC
    Menopause Int; 2007 Jun; 13(2):65-70. PubMed ID: 17540136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement therapy in breast cancer survivors.
    Kandil M
    Climacteric; 2010 Oct; 13(5):499. PubMed ID: 20738237
    [No Abstract]   [Full Text] [Related]  

  • 6. Options for hormone therapy in women who have had a hysterectomy.
    Haney AF; Wild RA
    Menopause; 2007; 14(3 Pt 2):592-7; quiz 598-9. PubMed ID: 17476150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation.
    Gérard C; Blacher S; Communal L; Courtin A; Tskitishvili E; Mestdagt M; Munaut C; Noel A; Gompel A; Péqueux C; Foidart JM
    J Endocrinol; 2015 Jan; 224(1):85-95. PubMed ID: 25359896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hot flashes and hormone use: harbingers of heart disease?
    Brinton EA
    Menopause; 2010 Mar; 17(2):223-5. PubMed ID: 20216272
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-estrogen-based treatments for menopausal symptoms.
    ; Pitkin J; Rees MC; Gray S; Lumsden MA; Marsden J; Stevenson JC; Williamson J
    Menopause Int; 2008 Jun; 14(2):88-90. PubMed ID: 18519272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depression and the menopause: why antidepressants are not enough?
    Graziottin A; Serafini A
    Menopause Int; 2009 Jun; 15(2):76-81. PubMed ID: 19465674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause.
    Gérard C; Arnal JF; Jost M; Douxfils J; Lenfant F; Fontaine C; Houtman R; Archer DF; Reid RL; Lobo RA; Gaspard U; Coelingh Bennink HJT; Creinin MD; Foidart JM
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):121-137. PubMed ID: 35306927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestins and recurrence in breast cancer survivors.
    Chlebowski RT; Anderson GL
    J Natl Cancer Inst; 2005 Apr; 97(7):471-2. PubMed ID: 15812065
    [No Abstract]   [Full Text] [Related]  

  • 13. Tibolone: the way to beat many a postmenopausal ailments.
    Lazovic G; Radivojevic U; Marinkovic J
    Expert Opin Pharmacother; 2008 Apr; 9(6):1039-47. PubMed ID: 18377345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis.
    Valéra MC; Noirrit-Esclassan E; Dupuis M; Fontaine C; Lenfant F; Briaux A; Cabou C; Garcia C; Lairez O; Foidart JM; Payrastre B; Arnal JF
    Mol Cell Endocrinol; 2018 Dec; 477():132-139. PubMed ID: 29928930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pros and cons of hormone replacement therapy.
    Brennan K; Ayres J
    Nurs Times; 2003 Sep 2-8; 99(35):26-7. PubMed ID: 14528753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women.
    Naunton M; Al Hadithy AF; Brouwers JR; Archer DF
    Menopause; 2006; 13(3):517-27. PubMed ID: 16735950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral investigational drugs currently in phase I or phase II for the amelioration of menopausal symptoms.
    Genazzani AR; Gaspard U; Foidart JM
    Expert Opin Investig Drugs; 2019 Mar; 28(3):235-247. PubMed ID: 30677323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menopause: introduction.
    McGarry KA
    Med Health R I; 2008 Mar; 91(3):72. PubMed ID: 18438095
    [No Abstract]   [Full Text] [Related]  

  • 19. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.
    Johansen OE; Qvigstad E
    Adv Ther; 2008 Jun; 25(6):525-51. PubMed ID: 18568306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms.
    Gérard C; Mestdagt M; Tskitishvili E; Communal L; Gompel A; Silva E; Arnal JF; Lenfant F; Noel A; Foidart JM; Péqueux C
    Oncotarget; 2015 Jul; 6(19):17621-36. PubMed ID: 26056044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.